Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biological versus Clinical Risk Factors in Acute Myeloid Leukemia: Is There a Winner?
Malagola M, Polverelli N, Cancelli V, Morello E, Turra A, Borlenghi E, Cattina F, Rambaldi B, Bernardi S, Zanaglio C, Dereli Eke E, Gandolfi L, Farina M, Russo D. Malagola M, et al. Among authors: borlenghi e. Case Rep Hematol. 2019 Jun 11;2019:3914828. doi: 10.1155/2019/3914828. eCollection 2019. Case Rep Hematol. 2019. PMID: 31281685 Free PMC article.
Peripheral blood WT1 expression predicts relapse in AML patients undergoing allogeneic stem cell transplantation.
Malagola M, Skert C, Ruggeri G, Turra A, Ribolla R, Cancelli V, Cattina F, Alghisi E, Bernardi S, Perucca S, Di Palma A, Borlenghi E, Pagani C, Rossi G, Caimi L, Russo D. Malagola M, et al. Among authors: borlenghi e. Biomed Res Int. 2014;2014:123079. doi: 10.1155/2014/123079. Epub 2014 Aug 17. Biomed Res Int. 2014. PMID: 25202702 Free PMC article.
Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.
Malagola M, Skert C, Borlenghi E, Chiarini M, Cattaneo C, Morello E, Cancelli V, Cattina F, Cerqui E, Pagani C, Passi A, Ribolla R, Bernardi S, Giustini V, Lamorgese C, Ruggeri G, Imberti L, Caimi L, Russo D, Rossi G. Malagola M, et al. Among authors: borlenghi e. Cancer Med. 2016 Feb;5(2):265-74. doi: 10.1002/cam4.593. Epub 2015 Dec 29. Cancer Med. 2016. PMID: 26715369 Free PMC article.
Bacterial Blood Stream Infections Negatively Impact on Outcome of Patients Treated with Allogeneic Stem Cell Transplantation: 6 Years Single-Centre Experience.
Malagola M, Rambaldi B, Ravizzola G, Cattaneo C, Borlenghi E, Polverelli N, Turra A, Morello E, Skert C, Cancelli V, Cattina F, Giannetta G, Bernardi S, Perucca S, Almici C, Roccaro A, Signorini L, Stellini R, Castelli F, Caruso A, Russo D. Malagola M, et al. Among authors: borlenghi e. Mediterr J Hematol Infect Dis. 2017 Jun 20;9(1):e2017036. doi: 10.4084/MJHID.2017.036. eCollection 2017. Mediterr J Hematol Infect Dis. 2017. PMID: 28698779 Free PMC article.
Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network.
Zappasodi P, Marbello L, Borlenghi E, Fumagalli M, Bernardi M, Fracchiolla N, Mancini V, Da Vià M, Ravano E, Cerqui E, Ferretti VV, Rocca B, Calvello C, Cazzola M, Castagnola C, Rossi G. Zappasodi P, et al. Among authors: borlenghi e. Ann Hematol. 2018 Nov;97(11):2107-2115. doi: 10.1007/s00277-018-3424-4. Epub 2018 Jul 15. Ann Hematol. 2018. PMID: 30009341 Clinical Trial.
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M, Farina M, Schieppati F, Borlenghi E, Bottelli C, Cerqui E, Ferrari S, Gramegna D, Pagani C, Passi A, Maifredi A, Tucci A, Capucci MA, Ruggeri G, Rossi G. D'Adda M, et al. Among authors: borlenghi e. Cancer. 2019 May 15;125(10):1674-1682. doi: 10.1002/cncr.31977. Epub 2019 Feb 1. Cancer. 2019. PMID: 30707758 Free article.
Invasive pulmonary aspergillosis in acute leukemia: a still frequent condition with a negative impact on the overall treatment outcome.
Cattaneo C, Gramegna D, Malagola M, Pagani C, Borlenghi E, Cerqui E, Passi A, Sciumé M, Bernardi S, Crippa C, Dalceggio D, Carbone C, Pelizzari AM, Re A, Russo D, Rossi G. Cattaneo C, et al. Among authors: borlenghi e. Leuk Lymphoma. 2019 Dec;60(12):3044-3050. doi: 10.1080/10428194.2019.1613535. Epub 2019 May 23. Leuk Lymphoma. 2019. PMID: 31120311
Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
Mannelli F, Gianfaldoni G, Bencini S, Piccini M, Cutini I, Bonetti MI, Scappini B, Pancani F, Ponziani V, Chiarini M, Borlenghi E, Bassan R, Rossi G, Bosi A. Mannelli F, et al. Among authors: borlenghi e. Am J Hematol. 2020 Nov;95(11):1304-1313. doi: 10.1002/ajh.25942. Epub 2020 Aug 19. Am J Hematol. 2020. PMID: 32697337 Free article. Clinical Trial.
74 results